{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:39:17Z","timestamp":1787495957809,"version":"build-2736575974"},"update-to":[{"DOI":"10.1002\/14651858.cd011741","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T00:00:00Z","timestamp":1496880000000}}],"reference-count":108,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011741.pub2","type":"journal-article","created":{"date-parts":[[2017,6,8]],"date-time":"2017-06-08T11:26:47Z","timestamp":1496921207000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Growth factors for angiogenesis in peripheral arterial disease"],"prefix":"10.1002","volume":"2017","author":[{"given":"Vitali","family":"Gorenoi","sequence":"first","affiliation":[{"name":"Hannover Medical School; Evidence based Medicine & Health Technology Assessment Working Group, Institute for Epidemiology, Social Medicine and Health Systems Research; Carl-Neuberg-Str. 1 Hannover Germany 30625"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael U","family":"Brehm","sequence":"additional","affiliation":[{"name":"Hannover Medical School; Department for Cardiology and Angiology; Carl-Neuberg-Str. 1 Hannover Germany 30265"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Koch","sequence":"additional","affiliation":[{"name":"Institute for Biometry, Hannover Medical School; Carl-Neuberg-Str. 1 Hannover Germany 30625"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Hagen","sequence":"additional","affiliation":[{"name":"Hannover Medical School; Evidence based Medicine & Health Technology Assessment Working Group, Institute for Epidemiology, Social Medicine and Health Systems Research; Carl-Neuberg-Str. 1 Hannover Germany 30625"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,6,8]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD011741.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1177\/1358836X0100600406","article-title":"Proteinuria in a placebo-controlled study of basic fibroblast growth factor for intermittent claudication","volume":"6","author":"Cooper","year":"2001","journal-title":"Vascular Medicine"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011741.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"S74","DOI":"10.1016\/S1525-0016(16)33791-1","article-title":"Long-term results of PCMV-VEGF165 intramuscular gene transfer in patients with chronic lower limb ischemia","volume":"23","author":"Bozo","year":"2015","journal-title":"Molecular Therapy"},{"issue":"5","key":"10.1002\/14651858.CD011741.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1074248415574336","article-title":"pCMV-vegf165 intramuscular gene transfer is an effective method of treatment for patients with chronic lower limb ischemia","volume":"20","author":"Deev","year":"2015","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0004|cit4","unstructured":"NCT00189540 Study of hepatocyte growth factor (HGF) via plasmid vector to improve perfusion in critical limb ischemia patients with peripheral ischemic ulcers clinicaltrials.gov\/ct2\/show\/NCT00189540"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jvs.2010.07.044","article-title":"Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial","volume":"52","author":"Powell","year":"2010","journal-title":"Journal of Vascular Surgery"},{"issue":"2","key":"10.1002\/14651858.CD011741.pub2-BIB0006|cit6","first-page":"451","article-title":"Safety and efficacy of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial","volume":"50","author":"Powell","year":"2009","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0007|cit7","unstructured":"NCT00060892 A Phase II Double-Blind, Randomized, Placebo-Controlled Study to Assess the Safety and Efficacy of AMG0001 to Improve Perfusion in Critical Leg Ischemia clinicaltrials.gov\/ct2\/show\/NCT00060892 (first received 15 May 2003)"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0010|cit8","unstructured":"Powell RJ Protocol#0207-546: a phase I\/II, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of AMG0001 to improve perfusion in critical leg ischemia Human Gene Therapy 2003 302 6"},{"issue":"3","key":"10.1002\/14651858.CD011741.pub2-BIB0008|cit9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1191\/1358863x04vm557oa","article-title":"Therapeutic angiogenesis for critical limb ischemia: design of the hepatocyte growth factor therapeutic angiogenesis clinical trial","volume":"9","author":"Powell","year":"2004","journal-title":"Vascular Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011741.pub2-BIB0009|cit10","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","article-title":"Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia","volume":"118","author":"Powell","year":"2008","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0011|cit11","first-page":"306-12, 399 (co","article-title":"Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia","volume":"23","author":"Kibbe","year":"2016","journal-title":"Gene Therapy"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0012|cit12","unstructured":"NCT01064440 Safety and efficacy study using gene therapy for critical limb ischemia clinicaltrials.gov\/ct2\/show\/NCT01064440?term=NCT01064440&rank=1"},{"issue":"12","key":"10.1002\/14651858.CD011741.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"A2092","DOI":"10.1016\/S0735-1097(14)62095-7","article-title":"A phase 2, double-blind, randomized, placebo-controlled, multicenter trial of the safety and efficacy of plasmid DNA expressing 2 isoforms of hepatocyte growth factor in patients with critical limb ischemia","volume":"63","author":"Perin","year":"2014","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0014|cit14","first-page":"S73","article-title":"Phase III comparison of intramuscular delivery of ANG1 (a vascular endothelial growth factor containing plasmid) with placebo in diabetic patients with critical limb ischaemia","volume":"3","author":"Kusumanto","year":"2001","journal-title":"Molecular Therapy"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/hum.2006.17.683","article-title":"Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial","volume":"17","author":"Kusumanto","year":"2006","journal-title":"Human Gene Therapy"},{"issue":"4","key":"10.1002\/14651858.CD011741.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/S0735-1097(00)00882-2","article-title":"Basic fibroblast growth factor in patients with intermittent claudication: results of a phase I trial","volume":"36","author":"Lazarous","year":"2000","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD011741.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"Makinen","year":"2002","journal-title":"Molecular Therapy"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0018|cit18","first-page":"392-5","article-title":"10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb","volume":"19","author":"Muona","year":"2012","journal-title":"Herttuala Gene Therapy"},{"issue":"10","key":"10.1002\/14651858.CD011741.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1089\/hum.2005.16.1202","article-title":"Arteriogenic gene therapy in patients with unreconstructable critical limb ischemia: a randomized, placebo-controlled clinical trial of adenovirus 5-delivered fibroblast growth factor-4","volume":"16","author":"Matyas","year":"2005","journal-title":"Human Gene Therapy"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0020|cit20","unstructured":"NCT00080392 EW-A-401 to treat intermittent claudication clinicaltrials.gov\/ct2\/show\/NCT00080392?term=NCT00080392&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0021|cit21","unstructured":"NCT00304837 VEGF gene transfer for critical limb ischemia clinicaltrials.gov\/ct2\/show\/NCT00304837?term=NCT00304837&rank=1"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011741.pub2-BIB0022|cit22","first-page":"770","article-title":"Assessment of safety and efficiency of intramuscular gene therapy with VEGF-2 in patients with critical limb ischaemia","volume":"100","author":"Rauh","year":"1999","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1016\/S0002-8703(03)00102-9","article-title":"Regional angiogenesis with vascular endothelial growth factor (VEGF) in peripheral arterial disease: design of the RAVE trial","volume":"145","author":"Rajagopalan","year":"2003","journal-title":"American Heart Journal"},{"issue":"16","key":"10.1002\/14651858.CD011741.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","article-title":"Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0025|cit25","unstructured":"AnGes MG Inc Academic release of data from phase III clinical trial of HGF gene therapy conducted in Japan. 2007 www.anges-mg.com\/en\/news"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0026|cit26","unstructured":"AnGes MG Inc Announcement of results of phase III clinical trials of HGF gene therapy in Japan. 2007 www.anges-mg.com\/en\/news"},{"issue":"9","key":"10.1002\/14651858.CD011741.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","article-title":"Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia","volume":"17","author":"Shigematsu","year":"2010","journal-title":"Gene Therapy"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0028|cit28","unstructured":"Yamada E Report on long-term data of collategene (HGF plasmid) - Japanese phase III study for CLI. 2010 www.anges-mg.com\/en\/news"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0029|cit29","unstructured":"NCT00368797 Efficacy and safety study of NV1FGF in patients with severe peripheral artery occlusive disease (TALISMAN 201) clinicaltrials.gov\/ct2\/show\/NCT00368797?term=NCT00368797&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011741.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Molecular Therapy"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD011741.pub2-BIB0031|cit31","first-page":"Abs P1497","article-title":"Dose and regimen effects of intramuscular NV1FGF in patients with critical limb ischemia: a randomized, double-blind, placebo controlled study","volume":"27","author":"Henry","year":"2006","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0032|cit32","unstructured":"NCT00798005 Efficacy and safety study of NV1FGF in patients with severe peripheral artery occlusive disease (TALISMAN 202) clinicaltrials.gov\/ct2\/show\/NCT00798005?term=NCT00798005&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0033|cit33","unstructured":"NCT01157871 Dose-finding, safety and efficacy study of NV1FGF in patients with intermittent claudication (TALISMAN 211) clinicaltrials.gov\/ct2\/show\/NCT01157871?term=NCT01157871&rank=1"},{"issue":"9781","key":"10.1002\/14651858.CD011741.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0035|cit35","unstructured":"NCT00566657 Efficacy and safety of XRP0038\/NV1FGF in critical limb ischemia patients with skin lesions (TAMARIS) clinicaltrials.gov\/ct2\/show\/NCT00566657?term=NCT00566657&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1878-6480(11)70240-3","article-title":"A randomized, double-blind placebo-controlled study of NV1FGF gene therapy in critical limb ischemia patients (TAMARIS Study). Rationale, design and baseline patient characteristics","volume":"3","author":"Belle","year":"2011","journal-title":"Archives of Cardiovascular Diseases. Supplements"},{"issue":"3","key":"10.1002\/14651858.CD011741.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.ejvs.2011.04.030","article-title":"Insights on the role of diabetes and geographic variation in patients with critical limb ischaemia","volume":"42","author":"Belle","year":"2011","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"issue":"9323","key":"10.1002\/14651858.CD011741.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1016\/S0140-6736(02)08937-7","article-title":"Therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (the TRAFFIC study): a randomised trial","volume":"359","author":"Lederman","year":"2002","journal-title":"Lancet"},{"issue":"2","key":"10.1002\/14651858.CD011741.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0002-9149(01)01622-8","article-title":"Design of the therapeutic angiogenesis with recombinant fibroblast growth factor-2 for intermittent claudication (TRAFFIC) trial","volume":"88","author":"Lederman","year":"2001","journal-title":"American Journal of Cardiology"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0040|cit40","unstructured":"NCT01548378 Safety and efficacy study using gene therapy for critical limb ischemia (NL003CLI-II) clinicaltrials.gov\/ct2\/show\/NCT01548378?term=NCT01548378&rank=1"},{"issue":"5","key":"10.1002\/14651858.CD011741.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"759","DOI":"10.2217\/14750708.2.5.759","article-title":"Efficacy of topical epidermal growth factor in healing diabetic foot ulcers","volume":"2","author":"Afshari","year":"2005","journal-title":"Therapy"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Anghel A Taranu G Seclaman E Rata A Tamas L Moldovan H Safety of vascular endothelial and hepatocyte growth factor gene therapy in patients with critical limb ischemia Current Neurovascular Research 2011 183 9","DOI":"10.2174\/156720211796558050"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0043|cit43","unstructured":"Biggs T Dulas D Duval S Goldman J Henry T Hirsch A Hepatocyte growth factor gene therapy for patients with critical limb ischemia: Results of a Phase I dose-escalation trial Catheterization and Cardiovascular Interventions 2009"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0044|cit44","unstructured":"C000000330 Peripheral blood mononuclear cell therapy in PAD patients with intermittent claudication randomized trial upload.umin.ac.jp\/cgi-open-bin\/ctr\/ctr.cgi?function=brows&action=brows&type=summary&recptno=R000000377&language=E"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0045|cit45","doi-asserted-by":"crossref","unstructured":"Capiod JC Tournois C Vitry F Sevestre MA Daliphard S Reix T Characterization and comparison of bone marrow and peripheral blood mononuclear cells used for cellular therapy in critical leg ischaemia: towards a new cellular product Vox Sanguinis 2009 256","DOI":"10.1111\/j.1423-0410.2008.01138.x"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0046|cit46","unstructured":"Choi ET Geraghty P Cooke C Schechtman K Link D Chambers CM Stem cell mobilization to treat severe peripheral artery disease (STEMPAD) 2012 Vascular Annual Meeting 2012"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0047|cit47","doi-asserted-by":"crossref","unstructured":"Creager MA Olin JW Belch JJ Moneta GL Henry TD Rajagopalan S Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication Circulation 2011 1765 73","DOI":"10.1161\/CIRCULATIONAHA.110.009407"},{"issue":"4","key":"10.1002\/14651858.CD011741.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.ejvs.2015.05.007","article-title":"Clinical safety and preliminary efficacy of plasmid pUDK-HGF expressing human hepatocyte growth factor (HGF) in patients with critical limb ischemia","volume":"50","author":"Cui","year":"2015","journal-title":"European Journal of Vascular and Endovascular Surgery"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0049|cit49","doi-asserted-by":"crossref","unstructured":"De Leeuw K Kusumanto Y Smit AJ Oomen P Van Der Hoeven JH Mulder NH Skin capillary permeability in the diabetic foot with critical limb ischaemia: the effects of a phVEGF165 gene product Diabetic Medicine 2008 1241 4","DOI":"10.1111\/j.1464-5491.2008.02557.x"},{"issue":"2","key":"10.1002\/14651858.CD011741.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.cct.2013.09.011","article-title":"Progenitor cell release plus exercise to improve functional performance in peripheral artery disease: the PROPEL study","volume":"36","author":"Domanchuk","year":"2013","journal-title":"Contemporary Clinical Trials"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0051|cit51","unstructured":"Doudar N El Ansary M Abdel Shafy S Stem cell implantation in the treatment of peripheral vascular disease Vox Sanguinis 2013 290"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/j.1742-481X.2009.00641.x","article-title":"Intra-lesional injections of recombinant human epidermal growth factor promote granulation and healing in advanced diabetic foot ulcers: multicenter, randomised, placebo-controlled, double-blind study","volume":"6","author":"Fern\u00e1ndez-Montequ\u00edn","year":"2009","journal-title":"International Wound Journal"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0053|cit53","unstructured":"Gavrilenko AV Voronov DA Konstantinov BA Bochkov NP Combination of reconstructive vascular operations with gene-engineering technologies of angiogenesis stimulation: a present-day policy aimed at improving the remote results of treating patients with lower limb chronic ischaemia Angiologiia I Sosudistaia Khirurgiia [Angiology and Vascular Surgery] 2008 49 53"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0054|cit54","doi-asserted-by":"crossref","unstructured":"Grossman PM Mendelsohn F Henry TD Hermiller JB Litt M Saucedo Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease American Heart Journal 2007 874","DOI":"10.1016\/j.ahj.2007.01.038"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0055|cit55","doi-asserted-by":"crossref","unstructured":"Huang P Li S Han M Xiao Z Yang R Han ZC Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes Diabetes Care 2005 2155","DOI":"10.2337\/diacare.28.9.2155"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0056|cit56","doi-asserted-by":"crossref","unstructured":"Huang PP Yang XF Li SZ Wen JC Zhang Y Han ZC Randomised comparison of G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow-mononuclear cells for the treatment of patients with lower limb arteriosclerosis obliterans Thrombosis and Haemostasis 2007 1335 42","DOI":"10.1160\/TH07-02-0137"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0057|cit57","unstructured":"JPRN-UMIN000002280 Randomized controlled trial of G-CSF-mobilized peripheral blood mononuclear cells transplantation for the treatment of patients with peripheral arterial disease apps.who.int\/trialsearch\/Trial2.aspx?TrialID=JPRN-UMIN000002280"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Kalka C Masuda H Takahashi T Gordon R Tepper O Gravereaux E Vascular endothelial growth factor165 gene transfer augments circulating endothelial progenitor cells in human subjects Circulation Research 2000 1198 202","DOI":"10.1161\/01.RES.86.12.1198"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Kirana S Stratmann B Prante C Prohaska W Koerperich H Lammers D Autologous stem cell therapy in the treatment of limb ischaemia induced chronic tissue ulcers of diabetic foot patients International Journal of Clinical Practice 2012 384 93","DOI":"10.1111\/j.1742-1241.2011.02886.x"},{"issue":"2","key":"10.1002\/14651858.CD011741.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jtcvs.2011.08.053","article-title":"Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product","volume":"144","author":"Lasala","year":"2012","journal-title":"Journal of Thoracic and Cardiovascular Surgery"},{"issue":"14 Suppl 1","key":"10.1002\/14651858.CD011741.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"E2020","DOI":"10.1016\/S0735-1097(11)62020-2","article-title":"Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of an autologous bone marrow-derived combination stem cell product","volume":"57","author":"Lasala","year":"2011","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0062|cit62","doi-asserted-by":"crossref","unstructured":"Matoba S Tatsumi T Murohara T Imaizumi T Katsuda Y Ito M Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia American Heart Journal 2008 1010 8","DOI":"10.1016\/j.ahj.2008.06.025"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0063|cit63","doi-asserted-by":"crossref","unstructured":"Mohammadzadeh L Samedanifard SH Keshavarzi A Alimoghaddam K Larijani B Ghavamzadeh A Therapeutic outcomes of transplanting autologous granulocyte colony-stimulating factor-mobilised peripheral mononuclear cells in diabetic patients with critical limb ischaemia Experimental and Clinical Endocrinology & Diabetes 2013 48 53","DOI":"10.1055\/s-0032-1311646"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0064|cit64","doi-asserted-by":"crossref","unstructured":"Mohler ER III Rajagopalan S Olin JW Trachtenberg JD Rasmussen H Pak R Adenoviral-mediated gene transfer of vascular endothelial growth factor in critical limb ischemia: safety results from a phase I trial Vascular Medicine (London) 2003 9 13","DOI":"10.1191\/1358863x03vm460oa"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0065|cit65","unstructured":"NCT01041417 Granulocyte-macrophage colony stimulating factor (GM-CSF) and mobilization of progenitor cells in peripheral arterial disease (GPAD-2) \/\/clinicaltrials.gov\/ct2\/show\/NCT01041417?term=NCT01041417&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0066|cit66","unstructured":"NCT01302015 Autologous adipose tissue derived mesenchymal stem cells transplantation in patient with Buerger's disease clinicaltrials.gov\/ct2\/show\/NCT01302015?term=NCT01302015&rank=1"},{"issue":"3","key":"10.1002\/14651858.CD011741.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1038\/gt.2011.85","article-title":"Long-term safety of intramuscular gene transfer of non-viral FGF1 for peripheral artery disease","volume":"19","author":"Niebuhr","year":"2012","journal-title":"Gene Therapy"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1358863X14557151","article-title":"Short-term treatment with a novel HIF-prolyl hydroxylase inhibitor (GSK1278863) failed to improve measures of performance in subjects with claudication-limited peripheral artery disease","volume":"19","author":"Olson","year":"2014","journal-title":"Vascular Medicine (London)"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0069|cit69","doi-asserted-by":"crossref","unstructured":"Ozturk A Kucukardali Y Tangi F Erikci A Uzun G Bashekim C Therapeutical potential of autologous peripheral blood mononuclear cell transplantation in patients with type 2 diabetic critical limb ischemia Journal of Diabetes and Its Complications 2012 29 33","DOI":"10.1016\/j.jdiacomp.2011.11.007"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0070|cit70","doi-asserted-by":"crossref","unstructured":"Perin ECS A randomized, controlled study of autologous therapy with bone marrow-derived aldehyde dehydrogenase bright cells in patients with critical limb ischemia Catheterization and Cardiovascular Interventions 2011 1060 7","DOI":"10.1002\/ccd.23066"},{"issue":"24","key":"10.1002\/14651858.CD011741.pub2-BIB0071|cit71","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1001\/jama.2013.282540","article-title":"Effect of progenitor cell mobilization with granulocyte-macrophage colony-stimulating factor in patients with peripheral artery disease: a randomized clinical trial","volume":"310","author":"Poole","year":"2013","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0072|cit72","doi-asserted-by":"crossref","unstructured":"Prochazka V Gumulec J Jaluvka F Salounova D Jonszta T Czerny D Cell therapy, a new standard in management of chronic critical limb ischemia and foot ulcer Cell Transplantation 2010 1413 24","DOI":"10.3727\/096368910X514170"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0073|cit73","doi-asserted-by":"crossref","unstructured":"Rajagopalan S Trachtenberg J Mohler E Olin J McBride S Pak R Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication American Journal of Cardiology 2002 512 6","DOI":"10.1016\/S1062-1458(02)00972-8"},{"issue":"8","key":"10.1002\/14651858.CD011741.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1001\/archdermatol.2011.84","article-title":"Topical treatment of hypertensive leg ulcers with platelet-derived growth factor-BB: a randomized controlled trial","volume":"147","author":"Senet","year":"2011","journal-title":"Archives of Dermatology"},{"issue":"2","key":"10.1002\/14651858.CD011741.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5114\/aoms.2013.39935","article-title":"Combined autologous bone marrow mononuclear cell and gene therapy as the last resort for patients with critical limb ischemia","volume":"11","author":"Skora","year":"2015","journal-title":"Archives of Medical Science"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Subramaniyam V Waller EK Murrow JR Manatunga A Lonial S Kasirajan K Bone marrow mobilization with granulocyte macrophage colony-stimulating factor improves endothelial dysfunction and exercise capacity in patients with peripheral arterial disease American Heart Journal 2009 53","DOI":"10.1016\/j.ahj.2009.04.014"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0077|cit77","doi-asserted-by":"crossref","unstructured":"Tateishi-Yuyama E Matsubara H Murohara T Ikeda U Shintani S Masaki H Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial Lancet 2002 427","DOI":"10.1016\/S0140-6736(02)09670-8"},{"issue":"3","key":"10.1002\/14651858.CD011741.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1191\/1358863x03vm496oa","article-title":"Design of the START-trial: STimulation of ARTeriogenesis using subcutaneous application of GM-CSF as a new treatment for peripheral vascular disease. A randomized, double-blind, placebo-controlled trial","volume":"8","author":"Royen","year":"2003","journal-title":"Vascular Medicine"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0079|cit79","doi-asserted-by":"crossref","unstructured":"Van Royen N Schirmer SH Atasever B Behrens CYH Ubbink D Buschmann EE A pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease Circulation 2005 1040 6","DOI":"10.1161\/CIRCULATIONAHA.104.529552"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1016\/j.avsg.2014.03.002","article-title":"Combination of autologous transplantation of G-CSF-mobilized peripheral blood mononuclear cells and panax notoginseng saponins in the treatment of unreconstructable critical limb ischemia","volume":"28","author":"Wang","year":"2014","journal-title":"Annals of Vascular Surgery"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0081|cit81","unstructured":"Wen J Autologous peripheral blood mononuclear cells transplantation in treatment of 30 cases of critical limb ischemia: 3-year safety follow-up Journal of Clinical Rehabilitative Tissue Engineering Research 2010 8526 30"},{"issue":"3","key":"10.1002\/14651858.CD011741.pub2-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/mt.2012.279","article-title":"DVC1-0101 to treat peripheral arterial disease: a phase I\/IIa open-label dose-escalation clinical trial","volume":"21","author":"Yonemitsu","year":"2013","journal-title":"Molecular Therapy"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3109\/14653240903518163","article-title":"Safety and efficacy of granulocytecolony-stimulating factor administration following autologous intramuscular implantation of bone marrow mononuclear cells: a randomized controlled trial in patients with advanced lower limb ischemia","volume":"12","author":"Zafarghandi","year":"2010","journal-title":"Cytotherapy"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0084|cit84","unstructured":"AnGes MG Inc AnGes announces amendment to the global development of HGF Plasmid for critical limb ischemia. 2016 www.anges-mg.com\/en\/news"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0085|cit85","unstructured":"AnGes MG Inc AnGes to start global phase III clinical trials of HGF gene therapy for critical limb ischemia in Europe. 2014 www.anges-mg.com\/en\/news"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0086|cit86","unstructured":"NCT02144610 Efficacy and safety of AMG0001 in subjects with critical limb ischemia (AGILITY) clinicaltrials.gov\/ct2\/show\/NCT02144610?term=NCT02144610&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0087|cit87","unstructured":"NCT00424866 FGF-1 for intramuscular injection for the treatment of peripheral arterial disease clinicaltrials.gov\/ct2\/show\/NCT00424866?term=NCT00424866&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0088|cit88","unstructured":"NCT02276937 Randomized Phase IIb Trial of DVC1-0101 clinicaltrials.gov\/ct2\/show\/NCT02276937?term=NCT02276937&rank=1"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jclinepi.2010.07.015","article-title":"GRADE guidelines: 3. Rating the quality of evidence","volume":"64","author":"Balshem","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"10","key":"10.1002\/14651858.CD011741.pub2-BIB0090|cit90","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003748.pub4","article-title":"Cilostazol for intermittent claudication","author":"Bedenis","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"12","key":"10.1002\/14651858.CD011741.pub2-BIB0091|cit91","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001368.pub4","article-title":"Naftidrofuryl for intermittent claudication","author":"Backer","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00380-008-1140-z","article-title":"Meta-analysis of randomized, controlled clinical trials in angiogenesis: gene and cell therapy in peripheral arterial disease","volume":"24","author":"Haro","year":"2009","journal-title":"Heart Vessels"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(13)61249-0","article-title":"Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis","volume":"382(9901)","author":"Fowkes","year":"2013","journal-title":"Lancet"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/HCR.0b013e31818c3b96","article-title":"Management of lower extremity peripheral arterial disease","volume":"28","author":"Gardner","year":"2008","journal-title":"Journal of Cardiopulmonary Rehabilitation and Prevention"},{"issue":"9","key":"10.1002\/14651858.CD011741.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1742-1241.2008.01842.x","article-title":"Gene therapy as a novel therapeutic option in the treatment of peripheral vascular disease: systematic review and meta-analysis","volume":"62","author":"Ghosh","year":"2008","journal-title":"International Journal of Clinical Practice"},{"issue":"5","key":"10.1002\/14651858.CD011741.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1024\/0301-1526\/a000298","article-title":"Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials","volume":"42","author":"Hammer","year":"2013","journal-title":"Vasa"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0097|cit97","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available at www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0098|cit98","doi-asserted-by":"publisher","first-page":"e463","DOI":"10.1161\/CIRCULATIONAHA.106.174526","article-title":"ACC\/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery\/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC\/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation","volume":"113","author":"Hirsch","year":"2006","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD011741.pub2-BIB0099|cit99","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000990.pub3","article-title":"Exercise for intermittent claudication","author":"Lane","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"S5A","DOI":"10.1016\/j.jvs.2006.12.037","article-title":"Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II)","volume":"45 Suppl S","author":"Norgren","year":"2007","journal-title":"Journal of Vascular Surgery"},{"issue":"3","key":"10.1002\/14651858.CD011741.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1358863X12438270","article-title":"Targets and delivery methods for therapeutic angiogenesis in peripheral artery disease","volume":"17","author":"Ouma","year":"2012","journal-title":"Vascular Medicine"},{"issue":"2","key":"10.1002\/14651858.CD011741.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.avsg.2008.12.003","article-title":"An update on therapeutic angiogenesis for peripheral vascular disease","volume":"24","author":"Pacilli","year":"2010","journal-title":"Annals of Vascular Surgery"},{"issue":"1","key":"10.1002\/14651858.CD011741.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jvs.2012.03.255","article-title":"Update on clinical trials evaluating the effect of biologic therapy in patients with critical limb ischemia","volume":"56","author":"Powell","year":"2012","journal-title":"Journal of Vascular Surgery"},{"key":"10.1002\/14651858.CD011741.pub2-BIB0104|cit104","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"18","key":"10.1002\/14651858.CD011741.pub2-BIB0105|cit105","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1161\/CIR.0b013e31822e80c3","article-title":"2011 ACCF\/AHA focused update of the guideline for the management of patients with peripheral artery disease (updating the 2005 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines","volume":"124","author":"Rooke","year":"2011","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD011741.pub2-BIB0106|cit106","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005262.pub3","article-title":"Pentoxifylline for intermittent claudication","author":"Salhiyyah","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"22","key":"10.1002\/14651858.CD011741.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1093\/eurheartj\/ehr211","article-title":"ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC)","volume":"32","author":"Tendera","year":"2011","journal-title":"European Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD011741.pub2-BIB0108|cit108","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011741","article-title":"Growth factors for angiogenesis in peripheral arterial disease","author":"Gorenoi","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD011741.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,17]],"date-time":"2023-09-17T03:19:25Z","timestamp":1694920765000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011741.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,6,8]]},"references-count":108,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011741.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,8]]}}}